Getting Ready Corporation (WPHM) news stock charts
Getting Ready Corporation (WPHM/WPHM.OB) Investment Summary:
Winston Pharmaceuticals, Inc., a pharmaceutical company, engages in the discovery, development, and commercialization of pain-management products primarily in the United States. Its product candidates span a range of pain indications, including osteoarthritis, neuropathic pain, cancer pain, post-surgical pain, episodic cluster headache, and chronic daily headache. The company?s flagship compound is Civamide, a TRPV-1 (transient receptor potential vanilloid-1) receptor modulator, which depresses the activity of the type-C pain fibers. Its product also includes doxepin hydrochloride, a Phase IIa completed for prophylaxis and the treatment of chronic daily headache. The company was founded in 1992 and is headquartered in Vernon Hills, Illinois.WINSTON PHARMACEUTICALS INC (WPHM:OTC Bulletin Board Market)
Snapshot of WINSTON PHARMACEUTICALS INC (WPHM)
|
OPEN
$0.20
|
PREVIOUS CLOSE
$0.20
|
|
|
DAY HIGH
$0.20
|
DAY LOW
$0.20
|
|
|
52 WEEK HIGH
03/27/09 - $2.99
|
52 WEEK LOW
01/25/10 - $0.06
|
|
|
MARKET CAP
15.5M
|
AVERAGE VOLUME 10 D
118.6
|
|
|
EPS TTM
--
|
SHARES OUTSTANDING
77.4M
|
|
|
WPHM Does Not Pay Dividends
|
P/E TTM
--
|
|
| K = Thousands M = Millions B = Billions | ||
Key developments for WINSTON PHARMACEUTICALS INC (WPHM)
Winston Pharmaceuticals, Inc. Presents at LCM 6th Annual Healthcare Conference, Nov-17-2009 through Nov-18-2009. Venue: The St. Regis, 2 East 55th Street, New York, NY 10022, United States.
Winston Pharmaceuticals Inc. announced that it has received a Notice of Non-compliance ('NON') from the Therapeutics Drug Directorate, Health Canada (the 'Directorate') for its New Drug Submission (NDS) for CIVANEX (zucapsaicin cream 0.075%) for the treatment of the signs and symptoms of osteoarthritis. The Directorate remarked that the analysis of the pivotal trial did not support the requested indication. Winston Labs has a period of ninety days to submit a response to the Directorate's NON, which it intends to do.
Winston Pharmaceuticals Inc. announced that Joel E. Bernstein, M.D. will resign as Chairman of the Board of Directors, President and Chief Executive Officer of the company, effective September 22, 2009, and that the company's Board of Directors has elected Jeffrey R. Bernstein, Ph.D. to assume the position of President and Chief Executive Officer, effective as of such date. The Board of Directors also appointed Robert A. Yolles, J. D., a member of the Company's Board of Directors since 2008, to assume the position of Chairman of the Board, effective September 22, 2009. Dr. Joel Bernstein will remain as a director of the Company and serve as a consultant, primarily in the areas of product and business development. Dr. Jeffrey Bernstein graduated Amherst College summa cum laude, was a Fulbright Scholar resident in Japan, and received an A.M. and Ph.D. in Business Economics from Harvard University. On September 30, 2007, Dr. Jeffrey Bernstein resigned from Winston Labs, and entered into a consulting agreement with such company, effective as of October 1, 2007. He has served as a consultant to Winston Labs since 2007, and to the Company since the consummation of its merger transaction with Winston Labs on September 25, 2008.
Getting Ready Corporation financial resources
WPHM Competitors
| Company | Last | Change | |
| No competitor information is available for WPHM. | |||
| Market data is delayed at least 15 minutes. | |||
Industry Analysis
| Valuation | WPHM | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 8.1x |
|
| Price/Book | 15.4x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 9.4x |
|
|
WPHM |
||
WPHM transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
More Recent Financial News About Getting Ready Corporation
WINSTON PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report
Read article
WINSTON PHARMACEUTICALS, INC. Files SEC form 10-K/A, Annual Report
Read article
WINSTON PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report
Read article
WINSTON PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report
Read article
WINSTON PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report
Read article